Dr. Cha has 15 years of R&D industry experience encompassing both large and small pharmaceutical/biotech companies, ranging from early-stage oncology studies to global late-stage oncology studies, involving various modalities and targets in Oncology. Since 2018 he has served as Vice President of Oncology at Samumed LLC, a privately held clinical-stage biotechnology company, leading the SM8502, a pan-CLK inhibitor, to clinic, in patients with refractory solid tumors. Prior to that Dr. Cha was a Senior Director, Global Clinical Lead at Pfizer focused on early oncology development. In his earlier roles Dr. Cha was Head of the metastatic breast cancer franchise at Puma Biotechnology, leading the global, registrational Phase 3 Study for neratinib in treatment of patients with metastatic HER2+ breast cancer in APAC, EU, South America, and North America, subsequently receiving the FDA approval in this indication.
Prior to Puma Biotechnology, at MEI Pharma he ran Phase II Studies with pracinostat, HDACi, in patients with AML and MDS. Prio to MEI, he worked on BOTOX in urological indications as a Medical Director. And, at Amgen, he worked on romiplostim (Nplate™), first-in-class thrombopoietin, getting global approval, and implementing REMS (Risk Evaluation and Mitigation Strategy) in the US, 5 post-marketing registries in the US, EU, and Canada, and involved in acquisition of blinatumomab, first-in-class BiTE (Bispecific T-cell Engager) to get the approval from FDA.
Dr. Cha received a BS in Biochemistry and Cell Biology from the University of California, San Diego and obtained his M.D. from the Tufts University School of Medicine. He has also completed Clinical Fellowship trainings in Hematology and Blood and Marrow Transplant at Stanford University School of Medicine.